Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2010-10-03 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including ordinary shares and share options, their terms, numbers, and escrow periods. It also includes sections on quotation of securities on the ASX, restricted securities, and convertible notes. The document is a formal announcement related to the issuance and quotation of new securities rather than a financial report or earnings release. It fits the description of a Capital/Financing Update, which covers company fundraising, financing activities, or capital structure changes. The document is lengthy (over 12,000 characters) and contains substantive details about the securities issued, consistent with a capital raising announcement rather than a brief notice or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2010-10-03 English
Annual Report to shareholders 75 pages ?Kb
Annual Report Classification · 100% confidence The document is titled 'FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2010' and contains detailed sections typical of an annual report, including chairman's address, CEO review, corporate governance statement, directors' report, comprehensive financial statements (income statement, balance sheet, cash flows), notes to financial statements, directors' declaration, auditor's independence declaration, and independent audit report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes detailed company information, market analysis, and financial data for the full fiscal year ending June 30, 2010. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance for the year. Therefore, the document should be classified as an Annual Report (10-K). FY 2010
2010-09-29 English
CBio Completes Lupus Research Study 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement dated 30 September 2010 from CBio Limited to the ASX Company Announcements Office. It reports the completion of animal studies for a lupus research study and mentions upcoming presentation of results at a scientific meeting. The content focuses on research progress and clinical trial updates rather than financial results or regulatory filings. There is no indication of financial statements, audit information, or management discussion. The document is a corporate announcement about research study completion and future presentation plans, which fits best under a general regulatory announcement category rather than a formal report or financial filing. The document length is 4718 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2010-09-29 English
Broker Presentation 19 pages ?Kb
Investor Presentation Classification · 95% confidence The document is titled 'Investment Presentation September 2010' and contains detailed information about the company's drug development, clinical trials, key directors, milestones, commercialization plans, financial requirements, and share capital. It is structured as a presentation aimed at investors, highlighting the company's strategy, progress, and funding needs. There are no full financial statements or comprehensive annual or quarterly financial reports included. The content is typical of an investor presentation rather than an earnings release, annual report, or regulatory filing. Therefore, the document fits best into the 'Investor Presentation' category.
2010-09-28 English
CBio Announces $9.3m Rights Issue 3 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an announcement dated 27 September 2010 from CBio Limited regarding a non-renounceable rights issue to raise capital. It details the offer terms, use of proceeds, important dates, and background information about the company and its lead product. The content focuses on fundraising activities and capital structure changes, specifically a rights issue offering new shares to existing shareholders. There are no financial statements or detailed financial performance data included, nor is this a report or presentation. The document is clearly an update on a capital raising event, which fits the definition of a Capital/Financing Update (CAP). The document length (6358 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive announcement about financing.
2010-09-26 English
Letter to ineligible shareholders 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a letter dated 27 September 2010 addressed to shareholders regarding a non-renounceable rights issue. It mentions a 'section 708AA Rights Issue Cleansing Notice and Information Booklet' related to the company's rights issue. The content focuses on informing shareholders about eligibility to participate in the rights issue and legal/regulatory considerations for shareholders outside Australia and New Zealand. The document is short (1053 characters) and serves as an announcement or notification about the rights issue rather than detailed financial data or a full report. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2010-09-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.